TNP-470 is primarily recognized for its anti-angiogenic properties, making it a significant compound in cancer research and treatment. It works by inhibiting the formation of new blood vessels, which tumors rely on for growth and metastasis. This mechanism has shown promise in reducing tumor size and slowing cancer progression in preclinical studies. Additionally, TNP-470 has been explored for its potential in treating other angiogenesis-dependent conditions, such as macular degeneration and rheumatoid arthritis. Its ability to target endothelial cells selectively has also sparked interest in its use for managing conditions involving abnormal blood vessel growth. Despite its potential, further research is needed to optimize its efficacy and minimize side effects in clinical applications.